Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
384757
Reference Type
Journal Article
Subtype
Review
Title
Current progress in targeted therapy for colorectal cancer
Author(s)
Ortega, J; Vigil, CE; Chodkiewicz, C
Year
2010
Is Peer Reviewed?
Yes
Journal
Cancer Control
ISSN:
1073-2748
Volume
17
Issue
1
Page Numbers
7-15
Language
English
PMID
20010514
URL
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20010514
Exit
Abstract
BACKGROUND: Several molecular targeting agents are available and being used in patients with colorectal cancer, and many others are being tested clinically. METHODS: The authors review and present the biology and use, including predictive testing, of the agents currently approved for use in colorectal cancer as well as current data on several newer tyrosine kinase inhibitors that are undergoing clinical trials. RESULTS: The angiogenesis inhibitor bevacizumab and the two EGFR inhibitors cetuximab and panitumumab are currently the three targeted agents approved in colorectal cancer. Recent studies show that the combined use of bevacizumab and EGFR inhibitors may lead to increased toxicity and inferior outcome. Much remains to be understood regarding these drugs and other targeted therapies as well as the underlying mechanism of tumor resistance or responsiveness to treatment. Their optimal use and sequencing with other treatment modalities such as surgery need to be further refined. CONCLUSIONS: There is a crucial need for identification of predictive markers of response and identification of possible negative interactions between targeted agents so that we can better select patients likely to respond to treatment.
Keywords
Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Colorectal Neoplasms/drug therapy/pathology/surgery/*therapy; Humans; 0 (Angiogenesis Inhibitors); 0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity